

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

IN THIS ISSUE (starts on next page)

Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs p 17

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 52 (Issue 1333)
March 8, 2010

www.medicalletter.org

Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with *Helicobacter pylori* who take aspirin or another NSAID have an especially high risk.¹ Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H₂-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing

antacids, the prostaglandin misoprostol (*Cytotec*, and others), and antibiotics to eradicate *H. pylori*.²

H₂-RECEPTOR ANTAGONISTS — NSAIDs are more likely to cause gastric than duodenal ulcers. High doses of an H₂-receptor antagonist have been shown to prevent NSAID-related gastric ulcers. In a 6-month study in patients on long-term NSAID therapy, famotidine 40 mg twice daily was significantly superior to placebo in preventing gastric ulcers found on endoscopy, which occurred in 20% of placebo-treated patients and 8% of those on famotidine.³ In a 12-

Table 1. Some Drugs for Prevention of Peptic Ulcers

Drug	Formulation	Dosage	Cost ¹
Proton Pump Inhibitors			
Esomeprazole ²⁻⁴ - <i>Nexium</i> (AstraZeneca)	20, 40 mg caps ⁵	20-40 mg once daily	\$195.06
Lansoprazole ^{2-4,6-8} – generic	15, 30 mg tabs, caps, ODT	15-30 mg once daily ⁹	176.93
<i>Prevacid</i> (Takeda)			179.94
Omeprazole ^{4,6-8} – generic	10, 20, 40 mg caps	20-40 mg once daily ⁹	119.40
<i>Prilosec</i> (AstraZeneca)			169.75
<i>Zegerid</i>	20, 40 mg caps ^{5,10}		167.74
Pantoprazole ¹¹ – generic			122.70
<i>Protonix</i> (Wyeth)	20, 40 mg tabs	20-40 mg once daily	137.10
Rabeprazole ^{4,6} – <i>Aciphex</i> (Eisai)	20 mg tabs	20 mg once daily	188.39
H₂-Receptor Antagonists^{6-8,12}			
Cimetidine – generic	200, 300, 400, 800 mg tabs	200-400 mg bid	52.20
<i>Tagamet</i> (GlaxoSmithKline)			104.83
Famotidine – generic	20, 40 mg tabs	20-40 mg bid	4.00 ¹³
<i>Pepcid</i> (Merck)			116.80
Nizatidine – generic	150, 300 mg caps	150 mg once daily-bid	71.50
<i>Axid</i> (Lilly)	150, 300 mg caps ⁵		96.38
Ranitidine – generic	150, 300 mg tabs, caps ⁵	150 mg once daily-bid	4.00 ¹³
<i>Zantac</i> (GlaxoSmithKline)	150, 300 mg tabs ⁵		122.83
Other Drugs			
Misoprostol ¹⁴ – generic	100, 200 mcg tabs	200 mcg bid-tid ¹⁴	71.95
<i>Cytotec</i> (Searle)			113.82

ODT = orally disintegrating tabs.

1. Cost for 30 days' treatment at the lowest dosage, according to AWP listings of prescription formulations in *Redbook* 2009 and *Redbook Update* February 2010.

2. FDA-approved for treatment of GERD.

3. FDA-approved for risk reduction of NSAID-associated gastric ulcers.

4. FDA-approved for *H. pylori* eradication to reduce risk of duodenal ulcer recurrence.

5. Also available as an oral suspension, syrup or solution.

6. FDA-approved for treatment of duodenal ulcers.

7. FDA-approved for treatment of gastric (benign) ulcers.

8. Also available over the counter, often at a much lower cost.

9. Lower dose is for GERD and duodenal ulcer; higher dose is for gastric ulcer.

10. Both strengths contain sodium bicarbonate 1.1 g; therefore, two 20-mg caps are not equivalent to a 40-mg cap.

11. FDA-approved for treatment of erosive esophagitis associated with GERD.

12. Twice the dose once daily in the evening is effective.

13. Price at some chain pharmacies.

14. FDA-approved only for prevention of NSAID-associated gastric ulcers.

week randomized, double-blind trial comparing famotidine 20 mg twice daily to placebo in 404 adult patients taking aspirin 75-325 mg daily with or without clopidogrel (*Plavix*) or dipyridamole (*Persantine*, and others), the prevalence of gastric ulcers found on endoscopy was 15% with placebo and 3.4% with famotidine, and that of duodenal ulcers was 8.5% and 0.5%, respectively.⁴ However, continued use of these agents leads to pharmacologic tolerance and loss of effectiveness over time.²

PROTON PUMP INHIBITORS (PPIs) — A randomized, double-blind trial in 169 patients taking NSAIDs compared omeprazole 20 mg once daily with placebo. After 6 months, the incidence of ulcers seen at endoscopy was 3.6% in the patients on omeprazole and 16.5% in those on placebo.⁵ A more recent 2-year study (VENUS) found that esomeprazole 20 or 40 mg once daily for 6 months was superior to placebo in preventing ulcers in NSAID users who had additional risk factors such as advanced age or a past history of ulcer; among 844 such patients, endoscopic ulcers developed in 20% with placebo, 5% with esomeprazole 20 mg, and 4% with esomeprazole 40 mg.⁶ Another trial compared esomeprazole 20 or 40 mg once daily with placebo in patients who were taking aspirin 75-325 mg daily and had one or more additional risk factors for ulceration, such as age over 65 or a past history of peptic ulcer disease; after 26 weeks, endoscopic ulcers were present in 7.4% of placebo-treated patients and in 1.1% and 1.5% of those on esomeprazole 20 or 40 mg, respectively.⁷

PPIs have been shown to be more effective than H₂-receptor antagonists in prevention of NSAID-related ulcers and at least as effective as misoprostol.^{8,9}

MISOPROSTOL — Misoprostol (*Cytotec*, and others), a synthetic prostaglandin E1 analog, can prevent gastric and duodenal ulcers in patients on chronic NSAID therapy. It may be as effective as a PPI, but requires multiple daily dosing and is not as well tolerated. Abdominal pain and dose-related diarrhea are the most common adverse effects of misoprostol. Nausea can also occur. Misoprostol is an abortifacient and is contraindicated during pregnancy.¹⁰

H. PYLORI ERADICATION — A meta-analysis of five prospective trials of *H. pylori* eradication showed a statistically significant reduction in the risk of endoscopic ulcers in patients who had not yet begun NSAID treatment, but not among those already taking an NSAID.¹¹ The American College of Gastroenterology now recommends considering routine testing for *H. pylori* before starting long-term therapy with an NSAID.¹

ANTACIDS — There is no convincing evidence that long-term use of aluminum- or magnesium-containing antacids can prevent development of peptic ulcers in patients taking aspirin or NSAIDs. Other problems with antacid use are the requirements for multiple daily doses and adverse effects on bowel habits: constipation with aluminum-containing products and diarrhea with magnesium.

CONCLUSION — Taking a proton pump inhibitor can prevent aspirin- or NSAID-associated ulcers detected on endoscopy. To what extent it prevents clinical symptoms or bleeding remains to be determined. □

1. FL Lanza et al. Guidelines for prevention of NSAID-related ulcer complications. *Am J Gastroenterol* 2009; 104:728.
2. Treatment of peptic ulcers and GERD. *Treat Guidel Med Lett* 2008; 6:55.
3. AS Taha et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. *N Engl J Med* 1996; 334:1435.
4. AS Taha et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. *Lancet* 2009; 374:119.
5. D Cullen et al. Primary gastroduodenal prophylaxis with omeprazole for nonsteroidal anti-inflammatory drug users. *Aliment Pharmacol Therap* 1998; 12:135.
6. JM Scheiman et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. *Am J Gastroenterol* 2006; 101:701.
7. JM Scheiman et al. Prevention of low-dose acetylsalicylic acid-associated gastric/duodenal ulcers with esomeprazole 20 mg and 40 mg once daily in patients at increased risk of ulcer development: a randomized controlled trial (OBERON). *Gastroenterology* 2009; 136:A-70 (abstract 412).
8. CJ Hawkey et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. *New Engl J Med* 1998; 338:727.
9. DY Graham et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. *Arch Intern Med* 2002; 162: 169.
10. Misoprostol. *Med Lett Drugs Ther* 1989; 31:21.
11. M Vergara et al. Meta-analysis: Role of *Helicobacter pylori* eradication in the prevention of peptic ulcer in NSAID users. *Aliment Pharmacol Ther* 2005; 21:1411.

The Medical Letter®
On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D.

EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School

EDITOR: Jean-Marie Pflomm, Pharm.D.

ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D.,
Blaine M. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.

CONSULTING EDITOR: Brinda M. Shah, Pharm.D.

ADVISORY BOARD:

Jules Hirsch, M.D., Rockefeller University

Gerald L. Mandell, M.D., University of Virginia School of Medicine

Dan M. Roden, M.D., Vanderbilt University School of Medicine

CONTRIBUTING EDITORS:

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons

Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School

Eric J. Epstein, M.D., Albert Einstein College of Medicine

David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario

Hans Meinertz, M.D., University Hospital, Copenhagen

Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine

F. Estelle R. Simons, M.D., University of Manitoba

Jordan W. Smoller, M.D., Sc.D., Harvard Medical School

Neal H. Steigbigel, M.D., New York University School of Medicine

SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey

EDITORIAL FELLOW: Vincent Teo, B.Sc. Phm, Sunnybrook Health Sciences Centre

MANAGING EDITOR: Susie Wong

ASSISTANT MANAGING EDITOR: Liz Donohue

PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona

FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski

DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino

VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by
Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address:

The Medical Letter, Inc.
1000 Main Street
New Rochelle, NY 10801-7537

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
Web Site: www.medicalletter.org
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$98; 2 years - \$167;
3 years - \$235. \$49.00 per year for
students, interns, residents and
fellows in the US and Canada.
CME: \$70 for 26 credits.

E-mail site license inquiries to:

info@medicalletter.org or call
800-211-2769 x315.
Special fees for bulk subscriptions.
Special classroom rates are available.
Back issues are \$12 each.
Major credit cards accepted.

Copyright 2010. ISSN 1523-2859